Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC 1740 in intermediate-risk HPV-positive locoregionally advanced oropharyngeal cancer
2023-508853-13-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2019
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of cisplatin, durvalumab and tremelimumab in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Event-free survival. Planned start Oct 2019; status: authorised.
02
Drugs
cisplatindurvalumabtremelimumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2023-508853-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508853-13-00.